Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Benzodiazepine

or Dissociative

or Ergoline

Use the filters below to narrow your results.

None (26) · Dalmane (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Doral (1) · DXM (1) · DXO (1) · Halcion (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Spravato (1) · Tranxene (1) · Versed (1) · Xanax (1)

None (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1)

None (42) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)

None (42) · 0.25 mg (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (42) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 28 mg/device (each dose uses 2 devices) (1)

None (42) · 10 mg/d (1) · 84 mg per session (1)

None (41) · Intranasal (under direct medical supervision) (1) · Oral (2)

None (41) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–60 minutes (1) · Within hours of first administration (1)

None (41) · 6 h (immediate-release); ~11 h (extended-release) (1) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (41) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 3–5 hours (1) · ~7-12 hours (1)

None (41) · 70–90% (oral) (1) · 80-90% oral (1) · ~48% intranasal (1)

None (41) · Avoid; may cause fetal harm (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Not established (1)

None (41) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1) · Schedule IV (US) (1)

Showing below up to 44 results in range #1 to #44.

2

2-FDCK

3

4

4-MeO-PCP

A

Alprazolam

B

Bromazepam

C

D

E

F

I

Ibogaine

L

M

N

O

P

Pyrazolam

Q

Quazepam

S

T

X

Xenon

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"